Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.

Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, Eder JP, Jones RL, Lu H, Ter Meulen J, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SM.

Clin Cancer Res. 2019 Jun 21. pii: clincanres.1025.2019. doi: 10.1158/1078-0432.CCR-19-1025. [Epub ahead of print]

PMID:
31227504
2.

First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1.

Mahipal A, Ejadi S, Gnjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, Kenney R, Odunsi K.

Cancer Immunol Immunother. 2019 Jul;68(7):1211-1222. doi: 10.1007/s00262-019-02331-x. Epub 2019 May 8.

PMID:
31069460
3.

Host tissue determinants of tumour immunity.

Salmon H, Remark R, Gnjatic S, Merad M.

Nat Rev Cancer. 2019 Apr;19(4):215-227. doi: 10.1038/s41568-019-0125-9. Review.

PMID:
30867580
4.

Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma.

Cohen AD, Lendvai N, Nataraj S, Imai N, Jungbluth AA, Tsakos I, Rahman A, Mei AH, Singh H, Zarychta K, Kim-Schulze S, Park A, Venhaus R, Alpaugh K, Gnjatic S, Cho HJ.

Cancer Immunol Res. 2019 Apr;7(4):658-669. doi: 10.1158/2326-6066.CIR-18-0198. Epub 2019 Feb 11.

PMID:
30745365
5.

Radiotherapy induces responses of lung cancer to CTLA-4 blockade.

Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, Heguy A, Imai N, Gnjatic S, Emerson RO, Zhou XK, Zhang T, Chachoua A, Demaria S.

Nat Med. 2018 Dec;24(12):1845-1851. doi: 10.1038/s41591-018-0232-2. Epub 2018 Nov 5.

6.

Immunohistochemical Detection of γ/δ T Lymphocytes in Formalin-fixed Paraffin-embedded Tissues.

Jungbluth AA, Frosina D, Fayad M, Pulitzer MP, Dogan A, Busam KJ, Imai N, Gnjatic S.

Appl Immunohistochem Mol Morphol. 2018 Mar 6. doi: 10.1097/PAI.0000000000000650. [Epub ahead of print]

PMID:
29517505
7.

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV.

Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13.

PMID:
29248319
8.

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, Zhang J, Loo J, Saglimbeni J, Abu-Akeel M, Zappasodi R, Riaz N, Smoragiewicz M, Kelley ZL, Basturk O; Australian Pancreatic Cancer Genome Initiative; Garvan Institute of Medical Research; Prince of Wales Hospital; Royal North Shore Hospital; University of Glasgow; St Vincent’s Hospital; QIMR Berghofer Medical Research Institute; University of Melbourne, Centre for Cancer Research; University of Queensland, Institute for Molecular Bioscience; Bankstown Hospital; Liverpool Hospital; Royal Prince Alfred Hospital, Chris O’Brien Lifehouse; Westmead Hospital; Fremantle Hospital; St John of God Healthcare; Royal Adelaide Hospital; Flinders Medical Centre; Envoi Pathology; Princess Alexandria Hospital; Austin Hospital; Johns Hopkins Medical Institutes; ARC-Net Centre for Applied Research on Cancer, Gönen M, Levine AJ, Allen PJ, Fearon DT, Merad M, Gnjatic S, Iacobuzio-Donahue CA, Wolchok JD, DeMatteo RP, Chan TA, Greenbaum BD, Merghoub T, Leach SD.

Nature. 2017 Nov 23;551(7681):512-516. doi: 10.1038/nature24462. Epub 2017 Nov 8.

9.

First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.

Pollack SM, Lu H, Gnjatic S, Somaiah N, O'Malley RB, Jones RL, Hsu FJ, Ter Meulen J.

J Immunother. 2017 Oct;40(8):302-306. doi: 10.1097/CJI.0000000000000183.

10.

Cancer Immunotherapy: From local to global.

Mulder WJM, Gnjatic S.

Nat Nanotechnol. 2017 Sep 6;12(9):840-841. doi: 10.1038/nnano.2017.196. No abstract available.

PMID:
28875982
11.

In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide.

Remark R, Merghoub T, Grabe N, Litjens G, Damotte D, Wolchok JD, Merad M, Gnjatic S.

Sci Immunol. 2016 Jul 14;1(1):aaf6925. doi: 10.1126/sciimmunol.aaf6925. Epub 2016 Jun 23.

PMID:
28783673
12.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

13.

Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging.

Hectors SJ, Wagner M, Bane O, Besa C, Lewis S, Remark R, Chen N, Fiel MI, Zhu H, Gnjatic S, Merad M, Hoshida Y, Taouli B.

Sci Rep. 2017 May 26;7(1):2452. doi: 10.1038/s41598-017-02706-z.

14.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

15.

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses.

Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH, Meinhof K, Chow A, Kim-Shulze S, Wolf A, Medaglia C, Li H, Rytlewski JA, Emerson RO, Solovyov A, Greenbaum BD, Sanders C, Vignali M, Beasley MB, Flores R, Gnjatic S, Pe'er D, Rahman A, Amit I, Merad M.

Cell. 2017 May 4;169(4):750-765.e17. doi: 10.1016/j.cell.2017.04.014.

16.

NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.

Szender JB, Papanicolau-Sengos A, Eng KH, Miliotto AJ, Lugade AA, Gnjatic S, Matsuzaki J, Morrison CD, Odunsi K.

Gynecol Oncol. 2017 Jun;145(3):420-425. doi: 10.1016/j.ygyno.2017.03.509. Epub 2017 Apr 6.

17.

MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy.

Laban S, Giebel G, Klümper N, Schröck A, Doescher J, Spagnoli G, Thierauf J, Theodoraki MN, Remark R, Gnjatic S, Krupar R, Sikora AG, Litjens G, Grabe N, Kristiansen G, Bootz F, Schuler PJ, Brunner C, Brägelmann J, Hoffmann TK, Perner S.

Oncotarget. 2017 Feb 28;8(9):14719-14735. doi: 10.18632/oncotarget.14830.

18.

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.

Baumgaertner P, Costa Nunes C, Cachot A, Maby-El Hajjami H, Cagnon L, Braun M, Derré L, Rivals JP, Rimoldi D, Gnjatic S, Abed Maillard S, Marcos Mondéjar P, Protti MP, Romano E, Michielin O, Romero P, Speiser DE, Jandus C.

Oncoimmunology. 2016 Sep 9;5(10):e1216290. eCollection 2016.

19.

Host-Protozoan Interactions Protect from Mucosal Infections through Activation of the Inflammasome.

Chudnovskiy A, Mortha A, Kana V, Kennard A, Ramirez JD, Rahman A, Remark R, Mogno I, Ng R, Gnjatic S, Amir ED, Solovyov A, Greenbaum B, Clemente J, Faith J, Belkaid Y, Grigg ME, Merad M.

Cell. 2016 Oct 6;167(2):444-456.e14. doi: 10.1016/j.cell.2016.08.076.

20.

A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF.

Chuang LS, Villaverde N, Hui KY, Mortha A, Rahman A, Levine AP, Haritunians T, Evelyn Ng SM, Zhang W, Hsu NY, Facey JA, Luong T, Fernandez-Hernandez H, Li D, Rivas M, Schiff ER, Gusev A, Schumm LP, Bowen BM, Sharma Y, Ning K, Remark R, Gnjatic S, Legnani P, George J, Sands BE, Stempak JM, Datta LW, Lipka S, Katz S, Cheifetz AS, Barzilai N, Pontikos N, Abraham C, Dubinsky MJ, Targan S, Taylor K, Rotter JI, Scherl EJ, Desnick RJ, Abreu MT, Zhao H, Atzmon G, Pe'er I, Kugathasan S, Hakonarson H, McCauley JL, Lencz T, Darvasi A, Plagnol V, Silverberg MS, Muise AM, Brant SR, Daly MJ, Segal AW, Duerr RH, Merad M, McGovern DP, Peter I, Cho JH.

Gastroenterology. 2016 Oct;151(4):710-723.e2. doi: 10.1053/j.gastro.2016.06.045. Epub 2016 Jul 1.

21.

HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer.

Szender JB, Eng KH, Matsuzaki J, Miliotto A, Gnjatic S, Tsuji T, Odunsi K.

Gynecol Oncol. 2016 Jul;142(1):158-162. doi: 10.1016/j.ygyno.2016.04.017. Epub 2016 Apr 23.

22.

Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J, Tung N, Chakarov S, Rivera C, Hogstad B, Bosenberg M, Hashimoto D, Gnjatic S, Bhardwaj N, Palucka AK, Brown BD, Brody J, Ginhoux F, Merad M.

Immunity. 2016 Apr 19;44(4):924-38. doi: 10.1016/j.immuni.2016.03.012.

23.

A multimodal imaging workflow to visualize metal mixtures in the human placenta and explore colocalization with biological response markers.

Niedzwiecki MM, Austin C, Remark R, Merad M, Gnjatic S, Estrada-Gutierrez G, Espejel-Nuñez A, Borboa-Olivares H, Guzman-Huerta M, Wright RJ, Wright RO, Arora M.

Metallomics. 2016 Apr;8(4):444-52. doi: 10.1039/c6mt00010j. Epub 2016 Mar 18.

24.

Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2.

Avogadri F, Gnjatic S, Tassello J, Frosina D, Hanson N, Laudenbach M, Ritter E, Merghoub T, Busam KJ, Jungbluth AA.

Am J Dermatopathol. 2016 Mar;38(3):201-7. doi: 10.1097/DAD.0000000000000362.

25.

Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck.

Veit JA, Heine D, Thierauf J, Lennerz J, Shetty S, Schuler PJ, Whiteside T, Beutner D, Meyer M, Grünewald I, Ritter G, Gnjatic S, Sikora AG, Hoffmann TK, Laban S.

Head Neck. 2016 Jul;38(7):1008-16. doi: 10.1002/hed.24403. Epub 2016 Feb 13.

26.

Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.

Matsuzaki J, Tsuji T, Luescher IF, Shiku H, Mineno J, Okamoto S, Old LJ, Shrikant P, Gnjatic S, Odunsi K.

Sci Rep. 2015 Oct 8;5:14896. doi: 10.1038/srep14896.

27.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

28.

Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.

de Moll EH, Fu Y, Qian Y, Perkins SH, Wieder S, Gnjatic S, Remark R, Bernardo SG, Moskalenko M, Yao J, Ferringer T, Chang R, Chipuk J, Horst BA, Birge MB, Phelps RG, Saenger YM.

Cancer Immunol Immunother. 2015 Sep;64(9):1193-203. doi: 10.1007/s00262-015-1726-0. Epub 2015 Jun 16.

29.

Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity.

Germain C, Gnjatic S, Dieu-Nosjean MC.

Front Immunol. 2015 Feb 23;6:67. doi: 10.3389/fimmu.2015.00067. eCollection 2015. Review.

30.

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.

Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg J, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N.

Cancer Immunol Res. 2015 Mar;3(3):278-287. doi: 10.1158/2326-6066.CIR-14-0202. Epub 2015 Jan 29.

31.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

32.

The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Remark R, Becker C, Gomez JE, Damotte D, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH, Powell CA, Altorki NK, Merad M, Gnjatic S.

Am J Respir Crit Care Med. 2015 Feb 15;191(4):377-90. doi: 10.1164/rccm.201409-1671PP. Review.

33.

Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs.

Alabanza L, Gnjatic S, Bhardwaj N, Brody J.

Oncoimmunology. 2014 Jan 3;3:e27580. eCollection 2014. No abstract available.

34.

Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer.

Parikh F, Duluc D, Imai N, Clark A, Misiukiewicz K, Bonomi M, Gupta V, Patsias A, Parides M, Demicco EG, Zhang DY, Kim-Schulze S, Kao J, Gnjatic S, Oh S, Posner MR, Sikora AG.

Cancer Res. 2014 Dec 15;74(24):7205-16. doi: 10.1158/0008-5472.CAN-14-1913. Epub 2014 Oct 15.

35.

Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer.

Daudi S, Eng KH, Mhawech-Fauceglia P, Morrison C, Miliotto A, Beck A, Matsuzaki J, Tsuji T, Groman A, Gnjatic S, Spagnoli G, Lele S, Odunsi K.

PLoS One. 2014 Aug 7;9(8):e104099. doi: 10.1371/journal.pone.0104099. eCollection 2014.

36.

NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.

Chen JL, Dawoodji A, Tarlton A, Gnjatic S, Tajar A, Karydis I, Browning J, Pratap S, Verfaille C, Venhaus RR, Pan L, Altman DG, Cebon JS, Old LL, Nathan P, Ottensmeier C, Middleton M, Cerundolo V.

Int J Cancer. 2015 Mar 15;136(6):E590-601. doi: 10.1002/ijc.29118. Epub 2014 Aug 14.

37.

Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.

Tyler EM, Jungbluth AA, Gnjatic S, O'Reilly RJ, Koehne G.

Cancer Immunol Res. 2014 Jun;2(6):547-58. doi: 10.1158/2326-6066.CIR-13-0174. Epub 2014 Mar 3.

38.

Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates.

Karbach J, Gnjatic S, Biskamp M, Atmaca A, Weidmann E, Brandt K, Wahle C, Bernhard H, Knuth A, Jäger E.

Cancer Immunol Res. 2014 May;2(5):404-9. doi: 10.1158/2326-6066.CIR-13-0200. Epub 2014 Feb 5.

39.

Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.

Tsuji T, Sabbatini P, Jungbluth AA, Ritter E, Pan L, Ritter G, Ferran L, Spriggs D, Salazar AM, Gnjatic S.

Cancer Immunol Res. 2013 Nov;1(5):340-50. doi: 10.1158/2326-6066.CIR-13-0089. Epub 2013 Sep 16.

40.

Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.

Matsuzaki J, Tsuji T, Luescher I, Old LJ, Shrikant P, Gnjatic S, Odunsi K.

Cancer Immunol Res. 2014 Apr;2(4):341-50. doi: 10.1158/2326-6066.CIR-13-0138. Epub 2013 Dec 17.

41.

Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.

Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, Beck A, Batt CA, Ritter G, Lele S, Gnjatic S, Karpf AR.

Cancer Immunol Res. 2014 Jan;2(1):37-49. doi: 10.1158/2326-6066.CIR-13-0126.

42.

Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer.

Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, Lepelley A, Becht E, Katsahian S, Bizouard G, Validire P, Damotte D, Alifano M, Magdeleinat P, Cremer I, Teillaud JL, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44. doi: 10.1164/rccm.201309-1611OC.

PMID:
24484236
43.

Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.

Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD.

Cancer Immunol Res. 2013 Oct;1(4):235-44. doi: 10.1158/2326-6066.CIR-13-0068.

44.

Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein.

Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, Nakayama E, Ishida T, Obata Y, Carver B, Scher H, Scardino PT, Slovin S, Subudhi SK, Reuter VE, Savage C, Allison JP, Melamed J, Jäger E, Ritter G, Old LJ, Gnjatic S.

Clin Cancer Res. 2013 Nov 15;19(22):6112-25. doi: 10.1158/1078-0432.CCR-12-3580. Epub 2013 Sep 30.

45.

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2013 Jun 3;11:137. doi: 10.1186/1479-5876-11-137.

46.

Ipilimumab for patients with advanced mucosal melanoma.

Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD.

Oncologist. 2013 Jun;18(6):726-32. doi: 10.1634/theoncologist.2012-0464. Epub 2013 May 28.

47.

A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence.

Judge JM, Brill LB 2nd, Smith KT, Deacon DH, Patterson JW, Grosh WW, Jungbluth AA, Gnjatic S, Slingluff CL Jr.

Cancer Immunol Immunother. 2013 Aug;62(8):1327-34. doi: 10.1007/s00262-013-1433-7. Epub 2013 May 12.

48.

Antigen depots: T cell traps?

Gnjatic S, Bhardwaj N.

Nat Med. 2013 Apr;19(4):397-8. doi: 10.1038/nm.3113. No abstract available.

PMID:
23558621
49.

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.

Maki RG, Jungbluth AA, Gnjatic S, Schwartz GK, D'Adamo DR, Keohan ML, Wagner MJ, Scheu K, Chiu R, Ritter E, Kachel J, Lowy I, Old LJ, Ritter G.

Sarcoma. 2013;2013:168145. doi: 10.1155/2013/168145. Epub 2013 Feb 27.

50.

Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes.

Hirayama M, Nishikawa H, Nagata Y, Tsuji T, Kato T, Kageyama S, Ueda S, Sugiyama D, Hori S, Sakaguchi S, Ritter G, Old LJ, Gnjatic S, Shiku H.

Eur J Immunol. 2013 Apr;43(4):989-1000. doi: 10.1002/eji.201242800. Epub 2013 Feb 26.

Supplemental Content

Loading ...
Support Center